• Jupiter Neurosciences posted a net loss of $2.06 million for quarter ended March 31, 2026, widening 35% from year-ago period.
• Net revenues were $18,652, swinging from no revenue a year earlier as Nugevia product shipments began in fourth-quarter 2025.
• General and administrative expense climbed 46% to $1.57 million, due to higher payroll and consulting costs plus expenses related to Nugevia.
• Research and development expense fell 12% to $411,049 on lower clinical trial and payroll and consulting costs.
• Cash and cash equivalents totaled $2.36 million at March 31, 2026, while net cash used in operating activities increased to $1.43 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023164), on May 14, 2026, and is solely responsible for the information contained therein.